Jeffrey M Venstrom
Overview
Explore the profile of Jeffrey M Venstrom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Stein S, Snider J, Ali S, Miksad R, Alexander B, Castellanos E, et al.
Future Oncol
. 2021 Aug;
17(31):4101-4114.
PMID: 34463133
To assess concordance between HER2 status measured by traditional methods and amplification measured by next-generation sequencing and its association with first-line trastuzumab clinical benefit in patients with advanced esophagogastric cancer....
12.
Necchi A, Cucchiara V, Grivas P, Bratslavsky G, Jacob J, Spiess P, et al.
Cancer
. 2021 Aug;
127(24):4557-4564.
PMID: 34379803
Background: This study assessed the contrasting genomic profiles from the primary tumors (PTs), metastatic (MET) sites, and circulating tumor DNA (ctDNA) of patients with prostate cancer (PC). Methods: A total...
13.
Sun H, Martin T, Marra J, Kong D, Keats J, Mace S, et al.
J Immunother Cancer
. 2021 Jul;
9(7).
PMID: 34272304
Background: Phase IIb clinical trial with isatuximab (Isa)-lenalidomide (Len)-dexamethasone (Dex) showed an improved progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma (RRMM), but the efficacy varied by...
14.
Tukachinsky H, Madison R, Chung J, Gjoerup O, Severson E, Dennis L, et al.
Clin Cancer Res
. 2021 Feb;
27(11):3094-3105.
PMID: 33558422
Purpose: Comprehensive genomic profiling (CGP) is of increasing value for patients with metastatic castration-resistant prostate cancer (mCRPC). mCRPC tends to metastasize to bone, making tissue biopsies challenging to obtain. We...
15.
Bolen C, Mattiello F, Herold M, Hiddemann W, Huet S, Klapper W, et al.
Blood
. 2021 Jan;
137(19):2704-2707.
PMID: 33512481
No abstract available.
16.
Schrock A, Lee J, Sandhu J, Madison R, Cho-Phan C, Snider J, et al.
Oncologist
. 2021 Jan;
26(6):469-475.
PMID: 33465286
Background: RAS short variant (SV) mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR) monoclonal antibody (EGFRmAb). However, the clinical implications for...
17.
Lin D, Killian J, Venstrom J, Ramkissoon S, Ross J, Elvin J
Mod Pathol
. 2020 Oct;
34(5):983-993.
PMID: 33077920
Malignant Brenner tumor is a rare primary ovarian carcinoma subtype that may present diagnostic and therapeutic conundrums. Here, we characterize the genomics of 11 malignant Brenner tumors, which represented 0.1%...
18.
Williams E, Sharaf R, Decker B, Werth A, Toma H, Montesion M, et al.
JCO Precis Oncol
. 2020 Oct;
4.
PMID: 33015533
Purpose: Leiomyosarcoma (LMS) harbors frequent mutations in and but few actionable genomic alterations. Here, we searched for recurrent actionable genomic alterations in LMS that occur in the absence of common...
19.
Madison R, Schrock A, Castellanos E, Gregg J, Snider J, Ali S, et al.
Lung Cancer
. 2020 Aug;
148:69-78.
PMID: 32823229
Objectives: Liquid biopsy and comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) are increasingly used for detection of targetable genomic alterations (GA) in non-small cell lung cancer (NSCLC). To...
20.
Comment L, Ward A, Schrock A, Fabrizio D, Venstrom J, Hegde P, et al.
Clin Pharmacol Ther
. 2020 Aug;
108(3):440-443.
PMID: 32744335
No abstract available.